Matteo Monami

List of Publications by Year
in descending order

186	9,790	34105 52	43889 91
papers	citations	h-index	g-index

189	189	189	10103
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology, 2011, 165, 687-701.	3.7	376
2	Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology, 2013, 168, 829-843.	3.7	343
3	Testosterone and Metabolic Syndrome: A Meta-Analysis Study. Journal of Sexual Medicine, 2011, 8, 272-283.	0.6	310
4	Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2011, 13, 221-228.	4.4	309
5	Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures. Diabetes Care, 2011, 34, 2474-2476.	8.6	241
6	Dipeptidyl peptidaseâ€4 inhibitors and cardiovascular risk: aâ€‰metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2013, 15, 112-120.	4.4	229
7	Efficacy and safety of sodium glucose coâ€transportâ€2 inhibitors in type 2 diabetes: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 457-466.	4.4	217
8	Cardiovascular safety of sulfonylureas: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2013, 15, 938-953.	4.4	201
9	Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Current Medical Research and Opinion, 2011, 27, 57-64.	1.9	198
10	Longâ€acting insulin analogues vs. NPH human insulin in type 1 diabetes. A metaâ€analysis. Diabetes, Obesity and Metabolism, 2009, 11, 372-378.	4.4	190
11	Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. Diabetes Research and Clinical Practice, 2008, 81, 184-189.	2.8	186
12	DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis. Advances in Therapy, 2012, 29, 14-25.	2.9	185
13	Autologous Cell Therapy for Peripheral Arterial Disease. Circulation Research, 2017, 120, 1326-1340.	4.5	181
14	Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients. Diabetes Care, 2008, 31, 199-203.	8.6	177
15	Sulphonylureas and cancer: a caseâ€“control study. Acta Diabetologica, 2009, 46, 279-284.	2.5	171
16	Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 604-612.	2.6	168
17	Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 689-697.	2.6	167
18	Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 224-235.	2.6	158

#	Article	IF	Citations
19	Safety issues with glucagonâ€like peptideâ€1 receptor agonists (pancreatitis, pancreatic cancer and) Tj ETQq1 1 0.784314 rgBT /Ove 2017, 19, 1233-1241.	4.4	155
20	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 38-47.	4.4	151
21	Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. European Journal of Endocrinology, 2009, 160, 909-917.	3.7	132
22	Hypoprolactinemia: A New Clinical Syndrome in Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2009, 6, 1457-1466.	0.6	123
23	Male Sexuality and Cardiovascular Risk. A Cohort Study in Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 1918-1927.	0.6	113
24	Low Testosterone is Associated with an Increased Risk of MACE Lethality in Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 1557-1564.	0.6	111
25	Liver enzymes and risk of diabetes and cardiovascular disease: Results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism: Clinical and Experimental, 2008, 57, 387-392.	3.4	109
26	Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients. Diabetes Care, 2010, 33, 1997-2003.	8.6	102
27	Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetologica, 2014, 51, 91-101.	2.5	100
28	Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients. Diabetes Care, 2011, 34, 129-131.	8.6	97
29	Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetologica, 2010, 47, 77-81.	2.5	95
30	Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes/Metabolism Research and Reviews, 2007, 23, 479-484.	4.0	93
31	Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials. Experimental Diabetes Research, 2011, 2011, 1-10.	3.8	93
32	Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Research and Clinical Practice, 2017, 130, 53-60.	2.8	93
33	Risk Factors Associated with Primary and Secondary Reduced Libido in Male Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2013, 10, 1074-1089.	0.6	91
34	Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes/Metabolism Research and Reviews, 2006, 22, 477-482.	4.0	90
35	Rosiglitazone and Risk of Cancer. Diabetes Care, 2008, 31, 1455-1460.	8.6	87
36	Serum PSA as a Predictor of Testosterone Deficiency. Journal of Sexual Medicine, 2013, 10, 2518-2528.	0.6	86

#	Article	IF	Citations
37	Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 48-56.	4.4	83
38	Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice, 2014, 103, 269-275.	2.8	81
39	Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials. Advances in Therapy, 2012, 29, 736-746.	2.9	80
40	The Diabetic Person Beyond a Foot Ulcer. Journal of the American Podiatric Medical Association, 2008, 98, 130-136.	0.3	79
41	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis. Experimental Diabetes Research, 2012, 2012, 1-8.	3.8	79
42	Shortâ€acting insulin analogues vs. regular human insulin in type 2 diabetes: a metaâ€analysis. Diabetes, Obesity and Metabolism, 2009, 11, 53-59.	4.4	77
43	Pioglitazone and cardiovascular risk. A comprehensive metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2008, 10, 1221-1238.	4.4	76
44	Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetologica, 2017, 54, 19-36.	2.5	75
45	Cardiac safety profile of rosiglitazone. International Journal of Cardiology, 2010, 143, 135-140.	1.7	65
46	Predictors of response to dipeptidyl peptidaseâ€4 inhibitors: evidence from randomized clinical trials. Diabetes/Metabolism Research and Reviews, 2011, 27, 362-372.	4.0	64
47	A metaâ€analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2014, 16, 833-840.	4.4	61
48	Sociodemographic and Clinical Features of Gender Identity Disorder: An Italian Multicentric Evaluation. Journal of Sexual Medicine, 2013, 10, 408-419.	0.6	60
49	Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetologica, 2017, 54, 933-941.	2.5	59
50	Low Diastolic Ambulatory Blood Pressure Is Associated with Greater Allâ€Cause Mortality in Older Patients with Hypertension. Journal of the American Geriatrics Society, 2009, 57, 291-296.	2.6	58
51	Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice, 2008, 79, 196-203.	2.8	57
52	Impairment of Couple Relationship in Male Patients with Sexual Dysfunction is Associated with Overt Hypogonadism. Journal of Sexual Medicine, 2009, 6, 2591-2600.	0.6	56
53	Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. Journal of Endocrinological Investigation, 2017, 40, 1251-1258.	3.3	54
54	All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes/Metabolism Research and Reviews, 2004, 20, 44-47.	4.0	52

#	Article	IF	Citations
55	Hormonal Association and Sexual Dysfunction in Patients with Impaired Fasting Glucose: A Cross-Sectional and Longitudinal Study. Journal of Sexual Medicine, 2012, 9, 1669-1680.	0.6	49
56	Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1106-1114.	2.6	49
57	Body Mass Index Regulates Hypogonadism-Associated CV Risk: Results from a Cohort of Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2011, 8, 2098-2105.	0.6	48
58	Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled studyâ€"the D.A.N.T.E (Diabetic ulcer Antimicrobial New) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.5	48
59	National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study. Diabetes, Obesity and Metabolism, 2008, 10, 430-435.	4.4	47
60	Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Journal of Developmental and Physical Disabilities, 2011, 34, 217-224.	3.6	46
61	Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. Journal of Endocrinological Investigation, 2014, 37, 477-495.	3.3	46
62	Sodiumâ€glucose coâ€transporterâ€2 (SGLTâ€2) inhibitors and cancer: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2019, 21, 1871-1877.	4.4	46
63	Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 159, 107981.	2.8	46
64	Skin autofluorescence in type 2 diabetes: Beyond blood glucose. Diabetes Research and Clinical Practice, 2008, 79, 56-60.	2.8	44
65	Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in Therapy, 2017, 34, 1-40.	2.9	43
66	Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetologica, 2012, 49, 307-314.	2.5	42
67	IDF and ATPâ€III definitions of metabolic syndrome in the prediction of allâ€cause mortality in type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2007, 9, 350-353.	4.4	41
68	Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?. Advances in Therapy, 2012, 29, 218-233.	2.9	41
69	Frequency of sexual activity and cardiovascular risk in subjects with erectile dysfunction: cross-sectional and longitudinal analyses. Andrology, 2013, 1, 864-871.	3.5	41
70	Short and mediumâ€term efficacy of sodium glucose coâ€transporterâ€2 (SGLTâ€2) inhibitors: A metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2018, 20, 1213-1222.	4.4	41
71	PCSK9 inhibitor therapy: A systematic review and metaâ€analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 903-908.	4.4	41
72	Childhood maltreatment in subjects with male-to-female gender identity disorder. International Journal of Impotence Research, 2011, 23, 276-285.	1.8	39

#	Article	IF	Citations
73	Effects of a Short Educational Program for the Prevention of Foot Ulcers in High-Risk Patients: A Randomized Controlled Trial. International Journal of Endocrinology, 2015, 2015, 1-5.	1.5	39
74	Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: A Meta-analysis. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 220-222.	1.2	38
75	Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 153, 138-144.	2.8	37
76	Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. International Journal of Cardiology, 2017, 240, 414-421.	1.7	36
77	Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 396-398.	2.6	36
78	Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Current Medical Research and Opinion, 2013, 29, 369-378.	1.9	35
79	Glucagonâ€like peptideâ€1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated metaâ€analysis and subgroup analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 203-211.	4.4	34
80	Metformin Beyond Diabetes: New Life for an Old Drug. Current Diabetes Reviews, 2006, 2, 307-315.	1.3	33
81	Factors associated with increased all-cause mortality during the COVID-19 pandemic in Italy. International Journal of Infectious Diseases, 2020, 98, 121-124.	3.3	32
82	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and allâ€cause mortality: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 1052-1056.	4.4	32
83	Isolated ambulatory hypertension is common in outpatients referred to a hypertension centre. Journal of Human Hypertension, 2004, 18, 897-903.	2.2	31
84	Impact of technology on glycaemic control in type 2 diabetes: A metaâ€analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes, Obesity and Metabolism, 2019, 21, 2619-2625.	4.4	31
85	Rate and Predictors of Hesitancy toward SARS-CoV-2 Vaccine among Type 2 Diabetic Patients: Results from an Italian Survey. Vaccines, 2021, 9, 460.	4.4	31
86	Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies. Vaccines, 2020, 8, 263.	4.4	30
87	Is Obesity a Further Cardiovascular Risk Factor in Patients with Erectile Dysfunction?. Journal of Sexual Medicine, 2010, 7, 2538-2546.	0.6	29
88	Severe Depressive Symptoms and Cardiovascular Risk in Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 3477-3486.	0.6	29
89	Type 1 diabetes and periodontitis: prevalence and periodontal destructionâ€”a systematic review. Acta Diabetologica, 2020, 57, 1405-1412.	2.5	29
90	Poor Response to Alprostadil ICI Test is Associated with Arteriogenic Erectile Dysfunction and Higher Risk of Major Adverse Cardiovascular Events. Journal of Sexual Medicine, 2011, 8, 3433-3445.	0.6	28

#	Article	IF	Citations
91	Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetologica, 2017, 54, 1101-1114.	2.5	28
92	Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetologica, 2020, 57, 689-696.	2.5	27
93	Pulse pressure and mortality in hypertensive type 2 diabetic patients. A cohort study. Diabetes/Metabolism Research and Reviews, 2006, 22, 172-175.	4.0	26
94	Fournier's gangrene and sodiumâ€glucose coâ€transporterâ€2 inhibitors: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 272-275.	4.4	26
95	Metabolic surgery for the treatment of type 2 diabetes: A network metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 1378-1387.	4.4	26
96	Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 699-704.	2.6	26
97	Comparison between different types of exercise training in patients with type 2 diabetes mellitus: A systematic review and network metanalysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1985-1992.	2.6	26
98	Treatment with Insulin Secretagogues and Cancer-Related Mortality in Type 2 Diabetic Patients A Retrospective Cohort Study. Experimental and Clinical Endocrinology and Diabetes, 2008, 116, 184-189.	1.2	25
99	Pulse Pressure and Prediction of Incident Foot Ulcers in Type 2 Diabetes. Diabetes Care, 2009, 32, 897-899.	8.6	25
100	Priapus is Happier with Venus than with Bacchus. Journal of Sexual Medicine, 2010, 7, 2831-2841.	0.6	25
101	Effects of probiotic supplementation during pregnancy on metabolic outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 162, 108111.	2.8	25
102	The Identification of Prediabetes Condition with ARIC Algorithm Predicts Long-Term CV Events in Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2013, 10, 1114-1123.	0.6	24
103	Glucose control in diabetes during home confinement for the first pandemic wave of COVID-19: a meta-analysis of observational studies. Acta Diabetologica, 2021, 58, 1603-1611.	2.5	24
104	Age-Related Changes in Treatment Strategies for Acute Myocardial Infarction: A Population-Based Study. Journal of the American Geriatrics Society, 2004, 52, 1355-1360.	2.6	23
105	Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. American Heart Journal, 2006, 151, 1094-1100.	2.7	23
106	Are comorbidity indices useful in predicting all-cause mortality in Type 2 diabetic patients? Comparison between Charlson index and disease count. Aging Clinical and Experimental Research, 2007, 19, 492-496.	2.9	23
107	Pulse Pressure Independently Predicts Major Cardiovascular Events in Younger But Not in Older Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2011, 8, 247-254.	0.6	23
108	Adiponectin, diabetes and ischemic heart failure: a challenging relationship. Cardiovascular Diabetology, 2012, 11, 151.	6.8	23

#	Article	IF	Citations
109	Fasting and post-prandial glucose and diabetic complication. A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 591-598.	2.6	22
110	Sars-CoV2 vaccine hesitancy in Italy: A survey on subjects with diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3243-3246.	2.6	22
111	Management of acute myocardial infarction in the real world: a summary report from The Ami-Florence Italian Registry. Internal and Emergency Medicine, 2008, 3, 109-115.	2.0	21
112	Winners and losers at the rosiglitazone gamble. Diabetes Research and Clinical Practice, 2008, 82, 48-57.	2.8	21
113	Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2745-2755.	2.6	21
114	Incidence and prognostic significance of hypoglycemia in hospitalized non-diabetic elderly patients. Aging Clinical and Experimental Research, 2006, 18, 446-451.	2.9	19
115	Adipokines as Possible New Predictors of Cardiovascular Diseases: A Case Control Study. Journal of Nutrition and Metabolism, 2012, 2012, 1-5.	1.8	19
116	Metabolic and Cardiovascular Outcomes of Fatherhood: Results from a Cohort of Study in Subjects with Sexual Dysfunction. Journal of Sexual Medicine, 2012, 9, 2785-2794.	0.6	19
117	Sexual and Cardiovascular Correlates of Male Unfaithfulness. Journal of Sexual Medicine, 2012, 9, 1508-1518.	0.6	19
118	Prostanoids in patients with peripheral arterial disease. Journal of Diabetes and Its Complications, 2016, 30, 161-166.	2.3	19
119	Finger Sepsis in Two Poorly Controlled Diabetic Patients With Reuse of Lancets. Diabetes Care, 2002, 25, 1103-1103.	8.6	18
120	Amphetamine derivatives and obesity. Appetite, 2009, 52, 405-409.	3.7	18
121	Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1601-1608.	2.6	18
122	Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine, 2020, 69, 504-507.	2.3	18
123	Is the Third Component of Metabolic Syndrome Really Predictive of Outcomes in Type 2 Diabetic Patients?. Diabetes Care, 2006, 29, 2515-2517.	8.6	17
124	Prognostic value of serum liver enzymes levels in type 2 diabetic patients. Diabetes/Metabolism Research and Reviews, 2007, 23, 625-630.	4.0	17
125	Saturation of critical care capacity and mortality in patients with the novel coronavirus (COVID-19) in Italy. Trends in Anaesthesia and Critical Care, 2020, 33, 33-34.	0.9	17
126	Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2539-2546.	2.6	17

#	Article	IF	Citations
127	Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies. Acta Diabetologica, 2016, 53, 35-40.	2.5	16
128	Protocol for a systematic review and individual patient data meta-analysis of prognostic factors of foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). BMC Medical Research Methodology, 2013, 13, 22.	3.1	15
129	Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?. Drug Safety, 2017, 40, 115-119.	3.2	15
130	Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 161, 108087.	2.8	15
131	Is Metabolic Syndrome a Useless Category in Subjects with High Cardiovascular Risk? Results from a Cohort Study in Men with Erectile Dysfunction. Journal of Sexual Medicine, 2011, 8, 504-511.	0.6	14
132	Autologous Skin Fibroblast and Keratinocyte Grafts in the Treatment of Chronic Foot Ulcers in Aging Type 2 Diabetic Patients. Journal of the American Podiatric Medical Association, 2011, 101, 55-58.	0.3	14
133	Are psychopathological features relevant predictors of glucose control in patients with type 2 diabetes? A prospective study. Acta Diabetologica, 2012, 49, 179-184.	2.5	14
134	Targeting educational therapy for type 2 diabetes: identification of predictors of therapeutic success. Acta Diabetologica, 2013, 50, 309-317.	2.5	14
135	Efficacy and safety of degludec insulin: a meta-analysis of randomised trials. Current Medical Research and Opinion, 2013, 29, 339-342.	1.9	14
136	Lipid levels in obese and nonobese subjects as predictors of fasting and postload glucose metabolism. Journal of Clinical Lipidology, 2012, 6, 132-138.	1.5	13
137	Italian guidelines for the treatment of type 2 diabetes. Acta Diabetologica, 2022, 59, 579-622.	2.5	13
138	Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) Study. Acta Diabetologica, 2009, 46, 191-196.	2.5	12
139	Periodontal disease and oral hygiene habits in a type 2 diabetic population. International Journal of Dental Hygiene, 2011, 9, 68-73.	1.9	12
140	Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine, 2021, 74, 508-517.	2.3	12
141	Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: the patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS). Acta Diabetologica, 2022, 59, 435-438.	2.5	12
142	All-cause and cardiovascular mortality in a consecutive series of patients with diabetic foot osteomyelitis. Diabetes Research and Clinical Practice, 2017, 131, 12-17.	2.8	11
143	Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 155, 107808.	2.8	11
144	Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1027-1034.	2.6	11

#	Article	IF	Citations
145	Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinology, 2020, , .	1.1	11
146	Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. International Journal of Cardiology, 2008, 126, 247-251.	1.7	10
147	Metabolic Syndrome and Cardiovascular Mortality in Older Type 2 Diabetic Patients: A Longitudinal Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 646-649.	3.6	10
148	Resistin level in coronary artery disease and heart failure. Journal of Cardiovascular Medicine, 2013, 14, 150-157.	1.5	10
149	Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetologica, 2017, 54, 411-413.	2.5	10
150	Combined continuous glucose monitoring and subcutaneous insulin infusion versus selfâ€monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2020, 22, 1286-1291.	4.4	10
151	Italian guidelines for the treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 770-814.	2.6	10
152	A randomized, open-label, controlled trial to evaluate the antimicrobial and surgical effect of CO2 laser treatment in diabetic infected foot ulcers: DULCIS (diabetic ulcer, CO2 laser, and infections) study. Journal of Endocrinological Investigation, 2017, 40, 985-989.	3.3	9
153	Alternative treatment or alternative to treatment? A systematic review of randomized trials on homeopathic preparations for diabetes and obesity. Acta Diabetologica, 2019, 56, 241-243.	2.5	9
154	Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?. Current Diabetes Reports, 2009, 9, 342-347.	4.2	8
155	Immune checkpoints inhibitors and hyperglycemia: A Meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 162, 108115.	2.8	8
156	Age and Comorbidity in Acute Myocardial Infarction: A Report From the AMI-Florence Italian Registry. The American Journal of Geriatric Cardiology, 2006, 15, 35-41.	0.6	7
157	Glucagon-Like Peptide-1 and Diabetes. Experimental Diabetes Research, 2011, 2011, 1-1.	3.8	7
158	CO2 laser for the treatment of diabetic foot ulcers with exposed bone. A consecutive series of type 2 diabetic patients. Journal of Endocrinological Investigation, 2017, 40, 819-822.	3.3	7
159	Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 529-536.	2.6	7
160	Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. Acta Diabetologica, 2010, 47, 7-11.	2.5	6
161	GLP-1 receptor agonist-induced polyarthritis: a case report. Acta Diabetologica, 2013, 51, 673-4.	2.5	6
162	Potential Impact of Climate on Novel Corona Virus (COVID-19) Epidemic. Journal of Occupational and Environmental Medicine, 2020, 62, e371-e372.	1.7	6

#	Article	IF	Citations
163	Rosiglitazone and cardiovascular risk. New England Journal of Medicine, 2007, 357, 938; author reply 939-40.	27.0	6
164	Prognostic value of dobutamine stress echocardiography in diabetic patients. International Journal of Cardiovascular Imaging, 2010, 26, 499-507.	1.5	5
165	Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 375-377.	2.6	5
166	Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 71-76.	2.6	5
167	The â€œEarly Treatmentâ€•Approach Reducing Cardiovascular Risk in Patients with TypeÂ2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. Diabetes Therapy, 2021, 12, 1445-1461.	2.5	5
168	All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 511-514.	2.6	5
169	Use of an Oxidized Regenerated Cellulose and Collagen Composite for Healing of Chronic Diabetic Foot Ulcers: A report of two cases. Diabetes Care, 2002, 25, 1892-1893.	8.6	4
170	Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al.. Diabetes Care, 2007, 30, 193-194.	8.6	4
171	Glucagon-Like Peptide-1 and Diabetes 2012. Experimental Diabetes Research, 2012, 2012, 1-1.	3.8	4
172	Coronary artery disease screening in type II diabetic patients: Prognostic value of rest and stress echocardiography. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 18-23.	3.6	4
173	Self-management in patients with type 2 diabetes: Group-based versus individual education. A systematic review with meta-analysis of randomized trails. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 330-336.	2.6	4
174	Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	2.6	4
175	Metformin may not reduce cardiovascular risk or all-cause mortality. Evidence-Based Medicine, 2013, 18, e13-e13.	0.6	3
176	Is early measurement of glycated albumin and HbA1c useful for the prediction of treatment response in type 2 diabetes?. Acta Diabetologica, 2016, 53, 669-672.	2.5	3
177	Deprescription in elderly patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2020, 170, 108498.	2.8	3
178	Major Amputation In Non-Healing Ulcers: Outcomes and Economic Issues. Data from a Cohort of Patients with Diabetic Foot Ulcers. International Journal of Lower Extremity Wounds, 2022, , 153473462210972.	1.1	3
179	Association between different screening strategies for SARSâ€CoVâ€2 and deaths and severe disease in Italy. International Journal of Clinical Practice, 2021, 75, e13867.	1.7	2
180	Left ventricular cavity obliteration during dobutamine stress echocardiography in diabetic patients. International Journal of Cardiovascular Imaging, 2012, 28, 1023-1033.	1.5	1

#	Article	IF	Citations
181	Hyperglycemia, hypoglycemia and glycemic variability in the elderly: a fatal triad?. Monaldi Archives for Chest Disease, 2016, 84, 726.	0.6	1
182	Retrospective Matched Case-Control Study on the Use of CO₂ Laser for the Treatment of Nonhealing Diabetic Foot Ulcers: The DULCIS-2 (Diabetic ULcer, CO₂ Laser, and Infections) Study. International Journal of Lower Extremity Wounds, 2022, 21, 471-476.	1.1	1
183	Reply to Jin-Qiu Yuan, Zu-Yao Yang, and Chen Mao's Letter to the Editor re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A Systematic Review and Meta-Analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with Î±-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol 2012;61:994â€“1003. European Urology, 2012, 62, e36-e38.	1.9	0
184	Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes?. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	0
185	Reply to Gaertner, K. and Frass, M.. Acta Diabetologica, 2019, 56, 247-247.	2.5	0
186	Reply to: Flaws in the meta-analysis of comparison between different types of exercise training in patients with type 2 diabetes mellitus: A letter to the editor. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	2.6	0